Prognosis Improves Over Time For Almost All Ovarian Cancer Survivors
Posted by Paul Cacciatore on May 7, 2008
Results showed that 5-year CS [conditional survival] improved for up to 5 years after diagnosis in almost all ovarian cancer groups, more than tripling in stage IV patients from 17 to 56 percent.
“Continuing prognosis improvement encouraging in ovarian cancer”
By Anita Wilkinson; 06 May 2008Gynecologic Oncology 2008; Advance online publication
“Medwire News: Encouraging study findings suggest that prognosis improves over time for almost all groups of ovarian cancer patients. Ovarian cancer survival is typically estimated from diagnosis, say Mehee Choi (The University of Texas Health Science Center at San Antonio, USA) and colleagues. However, they add that these projections are often discouraging and not necessarily pertinent for patients who have survived the initial treatment period, as prognosis after initial management is not static.
Believing conditional survival (CS) – the probability that patients who have survived for a designated period will be alive for another fixed interval – is more accurate, they applied this measure to 30,738 patients on a National Cancer Institute database [i.e., 1988 -2001 Surveillance Epidemiology and End Results (SEER) data]. Results showed that 5-year CS improved for up to 5 years after diagnosis in almost all ovarian cancer groups, more than tripling in stage IV patients from 17 to 56 percent. Patients with undifferentiated epithelioid histology saw 5-year CS increase from 29 percent at diagnosis to 84 percent after 5 years, and there were also big gains for those with serous histology. Choi et al conclude: ‘Five-year CS probability is an easily understandable measure that can be used to more accurately portray to a patient her current risk profile.’”
[Quoted Source: "Continuing prognosis improvement encouraging in ovarian cancer," by Anita Wilkinson, MedWire News Release dated May 6, 2008 (discussing the study entitled "Conditional survival in ovarian cancer: Results from the SEER dataset 1988-2001," Choi M. et. al., Gynecol Oncol. 2008 May;109(2):203-9)].